RNA binding motif protein 3: a potential biomarker in cancer and therapeutic target in neuroprotection

Ren-Bin Zhou; Xiao-Li Lu; Chen-Yan Zhang; Da-Chuan Yin

doi:10.18632/oncotarget.14755

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

RNA binding motif protein 3: a potential biomarker in cancer and therapeutic target in neuroprotection

Ren-Bin Zhou, Xiao-Li Lu, Chen-Yan Zhang and Da-Chuan Yin _

PDF | HTML | How to cite

Oncotarget. 2017; 8:22235-22250. https://doi.org/10.18632/oncotarget.14755

Metrics: PDF 3209 views | HTML 5648 views | ?

Abstract

Ren-Bin Zhou1, Xiao-Li Lu1, Chen-Yan Zhang1 and Da-Chuan Yin1

1 Key Laboratory for Space Bioscience & Biotechnology, School of Life Sciences, Northwestern Polytechnical University, Xi’an, Shaanxi, PR China

Correspondence to:

Da-Chuan Yin, email:

Keywords: RNA binding protein 3, cancer, biomarker, neuroprotection

Received: September 24, 2016 Accepted: January 10, 2017 Published: January 19, 2017

Abstract

RNA binding motif 3 (RBM3) is a highly conserved cold-induced RNA binding protein that is transcriptionally up-regulated in response to harsh stresses. Featured as RNA binding protein, RBM3 is involved in mRNA biogenesis as well as stimulating protein synthesis, promoting proliferation and exerting anti-apoptotic functions. Nowadays, accumulating immunohistochemically studies have suggested RBM3 function as a proto-oncogene that is associated with tumor progression and metastasis in various cancers. Moreover, emerging evidences have also indicated that RBM3 is equally effective in neuroprotection. In the present review, we provide an overview of current knowledge concerning the role of RBM3 in various cancers and neuroprotection. Additionally, its potential roles as a promising diagnostic marker for cancer and a possible therapeutic target for neuro-related diseases are discussed.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14755

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

RNA binding motif protein 3: a potential biomarker in cancer and therapeutic target in neuroprotection

Abstract